Celltrion Expands In APAC, Small Molecules Via $278m Takeda Asset Buy
Ongoing Divestments By Japanese Firm
In continuing strategy to shed non-core assets globally, Japanese firm will sell portfolio of selected products in Asia-Pacific to Korean biosimilars giant Celltrion.
You may also be interested in...
Helped by government support for the development of COVID-19 drugs and vaccines, Celltrion’s monoclonal antibody becomes the first therapeutic for the disease to be officially approved in South Korea.
Japanese major offers redundancy scheme as it looks to further tighten focus on core therapeutic areas, but no numerical targets given.
Japan’s largest pharma company says it has seen no impact on its financial results so far from the coronavirus pandemic, with continuing growth for mainstay drugs, and raises its profit forecasts for the fiscal year on favorable one-off factors.